Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder.

Canda A., Tuzel E., Mungan M. U., Yorukoglu K., Kirkali Z.

European urology, vol.45, no.4, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45 Issue: 4
  • Publication Date: 2004
  • Doi Number: 10.1016/j.eururo.2003.12.014
  • Journal Name: European urology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: bladder, transitional cell carcinoma, prostatic urethral involvement, carcinoma in situ, BCG, intravesical treatment, BACILLUS-CALMETTE-GUERIN, INTRAVESICAL BCG, CANCER, THERAPY, INSITU, IMMUNOTHERAPY
  • Dokuz Eylül University Affiliated: Yes


Objective: Treatment of patients with mucosal prostatic urethral transitional cell carcinoma (TCC) is controversial. In this study, we evaluated the outcome of patients with mucosal prostatic urethral TCC who were managed conservatively.